Cargando…
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A product containing daxibotulinumtoxinA with a stabilizing excipient peptide (RTP004). DAXI immunogenicity was assessed in three phase 3 glabellar line studies (two placebo-controlled, single-dose studies and an open-label rep...
Autores principales: | Gallagher, Conor J., Bowsher, Ronald R., Clancy, Amanda, Dover, Jeffrey S., Humphrey, Shannon, Liu, Yan, Prawdzik, Gregg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862169/ https://www.ncbi.nlm.nih.gov/pubmed/36668880 http://dx.doi.org/10.3390/toxins15010060 |
Ejemplares similares
-
Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
por: Humphrey, Shannon, et al.
Publicado: (2023) -
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)
por: Carruthers, Jean D., et al.
Publicado: (2020) -
Impact of Glabellar Injection Technique With DaxibotulinumtoxinA for Injection on Brow Position
por: Bertucci, Vince, et al.
Publicado: (2022) -
Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials
por: Solish, Nowell, et al.
Publicado: (2022) -
Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection
por: Glogau, Richard, et al.
Publicado: (2021)